Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
A phase 2 trial of Rituximab, Bortezomib and Ibritumomab tiuxetan in Mantle cell lymphoma, run by Duke University, recorded as terminated on the registry.
Overview
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT01497275 by Duke University, with 5 participants recorded, started 2012-02 and due to reach its primary completion in 2014-05. Interventions recorded: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan. Conditions recorded: Mantle-Cell Lymphoma.
Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialIbritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
Shares Ibritumomab tiuxetan, Rituximab and the tag pipeline.
- TrialA Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
Shares Ibritumomab tiuxetan and the tag pipeline.
- TrialPhase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Shares Mantle cell lymphoma, Rituximab and the tag pipeline.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Mantle cell lymphoma, Rituximab and the tag pipeline.
- TrialCD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Shares Mantle cell lymphoma and the tag pipeline.
- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Mantle cell lymphoma, Rituximab and the tag pipeline.
- TrialA Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
Shares Rituximab and the tag pipeline.
- TrialA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Shares Rituximab and the tag pipeline.